Granules India expects first-to-file status for Ruxolitinib tablets
In short
Granules India expects sole first-to-file status for Ruxolitinib Extended-Release Tablets. The summary says that, if the FDA confirms it and all rules are met, this could bring 180 days of generic exclusivity under US law.
This matters because exclusivity can protect sales for a short time. The reporting does not say the FDA has confirmed it yet.
What the reporting says
Granules India is expecting sole first-to-file status on Ruxolitinib Extended-Release Tablets, according to the BusinessLine summary. The reporting says that if the FDA confirms it and all statutory requirements are met, the status could provide 180 days of generic drug exclusivity under US law. The key unknown is whether FDA confirmation and eligibility are actually granted.
Why it matters
Granules India is reported to be expecting sole first-to-file status on Ruxolitinib Extended-Release Tablets. The summary says FDA confirmation and compliance with all statutory and regulatory requirements would be needed, and that the status could bring 180 days of generic exclusivity under US law. The reporting does not say whether the FDA has already approved the status or when a decision may come.